Detection of brain somatic mutations in CSF from refractory epilepsy patients Running head: Detect somatic variants in epilepsy patients CSF

Seyeon Kim, Sara Baldassari, Stéphanie Baulac, Jeong Ho Lee

▶ To cite this version:

Seyeon Kim, Sara Baldassari, Stéphanie Baulac, Jeong Ho Lee. Detection of brain somatic mutations in CSF from refractory epilepsy patients Running head: Detect somatic variants in epilepsy patients CSF. Annals of Neurology, 2021, 90 (4), pp.694-695. 10.1002/ana.26188 . hal-03474483

HAL Id: hal-03474483
https://hal.sorbonne-universite.fr/hal-03474483

Submitted on 10 Dec 2021

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.

Detection of brain somatic mutations in CSF from refractory epilepsy patients

Running head: Detect somatic variants in epilepsy patients CSF

Seyeon Kim, BS[1]*; Sara Baldassari, PhD[2]*; Nam Suk Sim, MD, PhD[1]; Mathilde Chipaux, MD, PhD[3]; Georg Dorfmüller, MD[3]; Dong Seok Kim, MD, PhD[4]; Won Seok Chang, MD, PhD[5]; Valérie Taly PhD[6], Jeong Ho Lee, MD, PhD[1,7+]; Stéphanie Baulac, PhD[2+]

Author Affiliations

[1] Graduate School of Medical Science and Engineering, KAIST, Daejeon, Korea
[2] Sorbonne Université, Institut du Cerveau - Paris Brain Institute - ICM, Inserm, CNRS, F-75013, Paris, France
[3] Department of Pediatric Neurosurgery, Rothschild Foundation Hospital, F-75019, Paris, France
[4] Department of Neurosurgery, Pediatric Neurosurgery, Severance Children's Hospital, Yonsei University College of Medicine, Seoul, Korea
[5] Department of neurosurgery, Brain Research Institute, Yonsei University College of Medicine, Seoul, Korea
[6] Centre de Recherche des Cordeliers, INSERM UMRS1138, CNRS SNC 5096, Sorbonne Université, USPC, Université de Paris, Equipe labellisée Ligue Nationale contre le cancer, Paris, France
[7] SoVarGen, Inc., Daejeon 34051, Korea.
* equally contributed
+ equally contributed

Corresponding authors

Jeong Ho Lee, M.D., Ph.D.
KAIST BioMedical Research Center (E7) Rm 7108
291 Daehak-ro, Yuseong-gu, Daejeon 34141, Republic of Korea
Tel: +82 42 350 4246 / Fax: +82 42 350 4240 / Email: jhlee4246@kaist.ac.kr or jhlee4246@gmail.com

Stéphanie Baulac, Ph.D.
Institut du Cerveau (ICM)
Hôpital Pitié-Salpêtrière - 47, bd de l'hôpital, 75013, Paris, France
Tel: +33 1 57 27 43 39 / Email: stephanie.baulac@icm-institute.org

Title character count: 77
Running head character count: 48
Number of words in abstract: 95
Number of words in main text: 1617
Number of figures: 1
Number of tables: 1
1 supplementary Table

37 **ABSTRACT**

38 Brain mosaic mutations are a major cause of refractory focal epilepsies with cortical malformations 39 such as focal cortical dysplasia, hemimegalencephaly, malformation of cortical development with 40 oligodendroglial hyperplasia in epilepsy, or ganglioglioma. Here, we collected cerebrospinal fluid 41 (CSF) during epilepsy surgery to search for somatic variants in cell-free DNA (cfDNA) using targeted 42 droplet digital PCR. In 3/12 epileptic patients with known somatic mutations previously identified in 43 brain tissue, we here provide evidence that brain mosaicism can be detected in the CSF-derived 44 cfDNA. These findings suggest future opportunities for detecting the mutant allele driving epilepsy 45 in CSF.

46

47 **Keywords**

48 Brain mosaicism, refractory epilepsy, cortical malformations, CSF, somatic variants, cell-free DNA

49

50

51

52

53

54

55

56

57

58

59

INTRODUCTION

Brain somatic variants have been shown to be an important etiology of structural intractable epilepsy.[1-4] We recently reported that brain mosaic variants give rise to early-onset epilepsies associated with various focal cortical malformations, including focal cortical dysplasia type 2 (FCD2), hemimegalencephaly (HME), malformation of cortical development with oligodendroglial hyperplasia in epilepsy (MOGHE), and ganglioglioma (GG), a low-grade neuronal-glial tumor.[2-11] Epilepsy associated with these aforementioned brain lesions is commonly pharmacoresistant to antiepileptics, and surgical resection of the epileptogenic zone is often the only treatment option effective at controlling seizures. While the genetic etiology of these disorders is now mostly known, molecular diagnosis requires genomic DNA derived from resected brain tissues, thus limiting a complete genetic assessment in cases not eligible for surgery.

Liquid biopsy techniques based on the sequencing of cell-free DNA (cfDNA) are emerging as non-invasive methods for tumor diagnosis and progression.[12] Interestingly, cerebrospinal fluid (CSF) has been shown to be a source of circulating tumor DNA released upon tumor cell death and a potentially powerful biomarker for the diagnosis and characterization of tumors of the central nervous system (CNS), such as gliomas.[13-15] Moreover, aberrant neuronal death has also been observed in epilepsy patients and experimental animal models.[16-18] To date, however, the clinical and diagnostic utility of liquid biopsies from patients with intractable epilepsy and brain malformations has not yet been addressed. Here, we provide evidence in epileptic patients with previously identified mutations in the brain resected tissues, that somatic mutations can be detected in the CSF-derived cfDNA collected during epilepsy surgery.

84 **METHODS**

85 **Patient cohort**

86 We collected brain tissues, blood and cerebrospinal fluid (CSF) samples from a cohort of 12 patients
87 (mean age 6.3 years at surgery) with lesional refractory epilepsy from France at the Fondation
88 Rothschild (n=5) and South Korea at the Severance children's hospital (n=7). Neuropathological
89 diagnoses were established by expert pathologists according to the ILAE classification for cortical
90 malformations and the WHO classification for tumors. The cohort comprised FCD2 (n=1), HME
91 (n=5), MOGHE (n=3), and GG (n=3) cases. Informed consent for the use of biological samples was
92 obtained from all patients. The study protocol received approval by the ethical committees of CPP Ile
93 de France II (N° ID-RCB/EUDRACT-2015-A00671-48) and Severance Hospital and the KAIST
94 Institutional Review Board and Committee on Human Research.

95 **Cerebrospinal fluid sampling and DNA extraction**

96 All CSF samples were collected after dura opening before surgery (resection or hemispherotomy).
97 For all KR samples and FR-4 sample (8/12), CSF was collected from the subarachnoid space adjacent
98 to the epileptogenic area; for FR-1, FR-2 and FR-3 cases, CSF was collected from the former resection
99 cavity; for FR-5, it was collected from the inter-hemispheric fissure. The volume of collected CSF
100 ranged from 1 to 6mL depending on the surgical site (See supplementary table for details). To remove
101 any genomic DNA contaminant from cells, all CSF samples (except case FR-4) were centrifuged at
102 400g for 5 min at 4°C (FR cases) or 2000g for 5 min at 4°C followed by 10000g for 5 min at 4°C
103 (KR cases). The supernatant was divided into 1mL aliquots and stored at -80°C. Cell-free DNA
104 (cfDNA) samples were extracted from 1mL of CSF (except 0.5mL of CSF for KR-3 sample) with the
105 Maxwell RSC cfDNA kit (Promega; French cohort) or the QIAamp circulating nucleic acid kit
106 (Qiagen; South Korean cohort) and quantified using the high sensitivity dsDNA Qubit assay (Thermo
107 Fisher Scientific). Using the same procedure described above, we also included cfDNA from 1mL of
108 CSF, collected from the subarachnoid space after dura opening, of three other refractory epileptic

109 patients with FCD1, FCD2a, and TSC, to be used as mutation-negative controls in the droplet digital
110 PCR assays.

111 **Droplet digital PCR assays and statistical analysis**

112 The droplet digital PCR (ddPCR) QX200 system (Bio-Rad) was used for variant specific detection.
113 All cfDNA samples were first subjected to a mutation-site targeted 13 cycles preamplification (for
114 each variant to test) with the SsoAdvanced™ PreAmp Supermix (Bio-Rad), optimized for unbiased
115 target-specific preamplification of a limited amount of DNA, following the standard protocol for 20X
116 TaqMan Assays. To avoid possible amplification errors, at least 2 independent preamplifications were
117 done per sample. Diluted (1ng/µL) bulk brain DNAs were also preamplified to control for ddPCR
118 accuracy. All ddPCR reactions were done in replicates (at least 2 replicates for controls, ≥3 for
119 patients) using the ddPCR Supermix for probes according to the manufacturer's protocol. ddPCR
120 mutation detection assays FAM+HEX (Bio-Rad) were purchased to detect the following variants:
121 *MTOR* p.Ser2215Phe, *MTOR* p.Ala1459Asp, *AKT3* p.Glu17Lys, *PIK3CA* p.Glu545Lys, *SLC35A2*
122 p.Ser212Leufs*9, *SLC35A2* p.Glu254*, *SLC35A2* p.Gln168*, and *BRAF* p.Val600Glu. In each assay,
123 3 to 5 mutation-negative cfDNAs controls (either the mutated patients used as crossed negative
124 controls or the 3 mutation-negative controls) were preamplified and assessed by ddPCR. In all
125 reactions, 5U of HindIII digestion enzyme was added. Amplification products were run on a QX200
126 droplet reader and data analyzed with the Quantasoft Analysis Pro software (version 1.0.596). To
127 ensure sufficient sensitivity, only assays with > 100 copies/µL of WT (HEX+) DNA were kept for
128 analysis. The VAF was calculated for each sample by the Quantasoft Analysis Pro software as the
129 fractional abundance of mutant (FAM+) to total (wild type (HEX+) + mutant (FAM+)) DNA copies.
130 Two-tailed t test (unequal variance) was used to assess if the average VAFs were statistically different
131 between the mutated patient and the mutation-negative controls.

132

133

134 **RESULTS**

135 We assembled a collection of CSF samples from 12 neurosurgery cases of FCD2, HME, MOGHE,
136 and GG with known mosaic pathogenic variant identified in the genomic DNA from the resected
137 frozen brain specimen (absent from blood samples indicating their brain-specificity): brain variants
138 in genes of the mTOR pathway (*PIK3CA*, *AKT3*, *MTOR*) in FCD2 and HME subjects (n=6);[9,10] brain
139 somatic variants in the galactose transporter encoding gene *SLC35A2* in MOGHE cases (n=3);[8,9,11]
140 and the recurrent brain somatic *BRAF* p.Val600Glu variant in GG patients (n=3) (**Table 1, Fig. 1**).[3,10]
141 We asked whether brain somatic variants can be detected in cfDNA from the patients' CSF collected
142 from the subarachnoid or ventricle space during epilepsy surgery. Since cfDNA concentrations from
143 CSF were generally low (mean 0.38ng/µL, range 0.05-2.7ng/µL, total amount of collected cfDNA
144 ranged from 0.27ng to 28ng) (Supplementary Table 1), we performed a targeted preamplification for
145 all cfDNA samples. We set up a droplet digital PCR (ddPCR) mutation detection assay to detect the
146 presence of a given variant in the matched cfDNA sample. To exclude potential amplification bias or
147 errors, we compared the mean VAF of patients versus mutation-negative controls. We obtained
148 significant p-values in 3 out of 12 patients: one HME (FR-4) with a CSF cfDNA VAF of 1.358% for
149 *PIK3CA* p.Glu545Lys; one GG (KR-7) with a CSF cfDNA VAF of 0.214% for *BRAF* p.Val600Glu,
150 and one MOGHE (KR-4) with a CSF cfDNA VAF of 0.145% for *SLC35A2* p.Gln168*. Variant allele
151 frequencies in the brain samples ranged from 1 to 24% in the whole cohort. There was no obvious
152 correlation between VAFs in the brain tissue and cfDNA samples.

153

154

155

156

157

DISCUSSION

Currently, identification of brain somatic mutations relies on direct access to brain tissue from epilepsy surgery for both cortical malformations and GG lesions. Achieving a genetic diagnosis before surgery (or when surgery is not possible) may help in understanding mutation-related disease prognoses and adopting targeted therapies. We hypothesized that mutated DNA could be detected in CSF-derived cfDNA from patients with non-tumoral cortical malformations, as described for other CNS malignant tumors. By using a targeted ddPCR-based approach, we were able to detect somatic brain mutations in CSF-derived cfDNA in 3/12 (25%) surgical cases with a mean VAF of 0.57%. A recent study ~~with a sensitivity threshold to detect down to 0.25% mutant rates~~, reported the detection of somatic mutations from the cfDNA of 3 cases with focal epilepsies by ddPCR, ~~with a mean mutational burden of 6.8%~~: in one patient with subcortical band heterotopia (widespread mosaic variant in *LIS1* p.Lys64*, VAF at 9.4% in CSF from lumbar puncture and 13% in the blood); one patient with FCD2b (*TSC1* p.Phe581His*6, VAF at 7.8% in CSF from dural puncture and 2.8% in the resected tissue); and one with GG (*BRAF* p.Val600Glu, VAF at 3.2% in CSF from dural puncture and 20.4% in the tumor).[21]

Overall, these results raise several questions. First, we were not able to detect known somatic mutations in CSF cfDNA from a substantial proportion of patients, indicating that the detection of low VAF variants (<0.1%) still needs technical improvement before a clinical use of CSF for genetic testing in epileptic patients. Moreover, in current clinical practice the described approach can only be applied when the mutation is known or suspected (as for the recurrent *BRAF* p.Val600Glu mutation), using variant-specific approaches. Second, all CSF samples in this study were collected during brain surgery before resection (mostly from the subarachnoid space). Genetic diagnosis based on CSF-derived cfDNA would require the proof-of-concept that brain-specific variants can be detected in CSF obtained from lumbar puncture (thus in a pre-surgical assessment) and may require multiplexing ddPCR assays targeting recurrent variants. Third, it remains unknown whether mutated cells found

in FCD2/HME (e.g. dysmorphic neurons and balloon cells) and MOGHE samples undergo cell death and therefore release their DNA.

Recent advances have shown that tumor-derived cfDNA in CSF samples can be used as a biomarker for monitoring tumor progression and response to therapy.[15] Brain surgery is not always effective in treating seizures since only 30-50% of patients are seizure-free after the first surgery and multiple resections are needed in some cases. [20] Identification of mutated brain DNA in CSF may be of use in predicting possible seizure relapse and personalized therapy. Thus, this work opens new avenues for improving the diagnostic workflow of patients with various brain malformations and research on the pathological mechanisms and progression of refractory focal epilepsies.

ACKNOWLEDGEMENTS

We thank the families that took part in this study, and the neuropediatricians who referred the patients. We also thank the sequencing ICM core facility (iGenSeq). This work was funded by the European Research Council (N°682345 to SB), the "Investissements d'avenir" ANR-10-IAIHU-06 and ANR-18-RHUS-0005 program, the Suh Kyungbae Foundation (to J.H.L), the National Research Foundation of Korea (NRF) grant funded by the Korean government, Ministry of Science and ICT (No. 2019R1A3B2066619 to J.H.L), and Korean Health Technology R&D Project, Ministry of Health & Welfare, Republic of Korea (H15C3143).

Author Contributions

JHL and SB contributed to the conception and design of the study; SYK, SBal, NSS, MC, GD, DSK, WSC, and VT contributed to the acquisition and analysis of data; JHL, SB, SYK, SBal and NSS contributed to drafting the text and preparing the figures.

Potential Conflicts of Interest

Nothing to report.

207 **REFERENCES**

208 1. Poduri A, Gilad D. Evrony, Xuyu Cai, Christopher A. Walsh. Somatic Mutation, Genomic Variation,
209 and Neurological Disease. Science 2013;341(6141):1237758.

210 2. Marsan E, Baulac S. Mechanistic target of rapamycin (mTOR) pathway, focal cortical dysplasia and
211 epilepsy. Neuropathol. Appl Neurobiol 2018;44(1):6–17.

212 3. Koh HY, Lee JH. Brain somatic mutations in epileptic disorders. Mol Cells 2018;41(10):881–888.

213 4. D'Gama AM, Walsh CA. Somatic mosaicism and neurodevelopmental disease. Nat Neurosci
214 2018;21(11):1504–1514.

215 5. Lim JS, Kim W, Kang H-C, et al. Brain somatic mutations in MTOR cause focal cortical dysplasia
216 type II leading to intractable epilepsy. Nat Med 2015;21(4):395–400.

217 6. Lim JS, Gopalappa R, Kim SH, et al. Somatic Mutations in TSC1 and TSC2 Cause Focal Cortical
218 Dysplasia. Am J Hum Genet 2017;100(3):454–472.

219 7. Koh HY, Kim SH, Jang J, et al. BRAF somatic mutation contributes to intrinsic epileptogenicity in
220 pediatric brain tumors. Nat Med 2018;24(11):1662–1668.

221 8. Sim NS, Seo Y, Lim JS, et al. Brain somatic mutations in SLC35A2 cause intractable epilepsy with
222 aberrant N-glycosylation. Neurol Genet 2018;4(6):e294.

223 9. Baldassari S, Ribierre T, Marsan E, et al. Dissecting the genetic basis of focal cortical dysplasia: a
224 large cohort study. Acta Neuropathol 2019;138(6):885–900.

225 10. Nam Suk S, Ara K, Woo Kyeong K, et al. Precise detection of low - level somatic mutation in
226 resected epilepsy brain tissue. Acta Neuropathol 2019;138(6):901–912.

227 11. Thomas B, Till H, Sara B, et al. Frequent SLC35A2 brain mosaicism in mild malformation of cortical
228 development with oligodendroglial hyperplasia in epilepsy (MOGHE). Acta Neuropathol Commun
229 2020;9(1):1-13.

230 12. Schwarzenbach H, Hoon DSB, Pantel K. Cell-free nucleic acids as biomarkers in cancer patients. Nat
231 Rev Cancer 2011;11(6):426–437.

232 13. Pan W, Gu W, Nagpal S, et al. Brain tumor mutations detected in cerebral spinal fluid. Clin Chem
233 2015;61(3):514–522.

234 14. Wang Y, Springer S, Zhang M, et al. Detection of tumor-derived DNA in cerebrospinal fluid of
235 patients with primary tumors of the brain and spinal cord. Proc. Natl Acad Sci 2015;112(31):9704–
236 9709.

237 15. Miller AM, Shah H, Pentsova I, et al. Tracking tumour evolution in glioma through liquid biopsies of
238 cerebrospinal fluid. Nature 2019;565(7741):654–658.

239 16. Ekstrand JJ, Pouliot W, Scheerlinck P, Dudek FE. Lithium pilocarpine-induced status epilepticus in
240 postnatal day 20 rats results in greater neuronal injury in ventral versus dorsal hippocampus.
241 Neuroscience 2011;192:699–707.

242 17. Scholl EA, Dudek FE, Ekstrand JJ. Neuronal degeneration is observed in multiple regions outside the
243 hippocampus after lithium pilocarpine-induced status epilepticus in the immature rat. Neuroscience
244 2013;252:45–59.

245 18. Mao XY, Zhou HH, Jin WL. Redox-related neuronal death and crosstalk as drug targets: Focus on
246 epilepsy. Front Neurosci 2019;13;512.

247 19. McEwen AE, Leary SES, Lockwood CM. Beyond the Blood: CSF-Derived cfDNA for Diagnosis and
248 Characterization of CNS Tumors. Front Cell Dev Biol 2020;8:45.

249 20. Lamberink HJ, Otte WM, Blümcke I, et al. Seizure outcome and use of antiepileptic drugs after
250 epilepsy surgery according to histopathological diagnosis: a retrospective multicentre cohort study.
251 Lancet Neurol 2020;19(9):748–757.

252 21. Ye Z, Chatterton Z, Pflueger J, et al. Cerebrospinal fluid liquid biopsy for detecting somatic
253 mosaicism in brain. Brain Commun 2021;3(1):fcaa235.

Table 1. Genetic findings in cfDNA and brain tissue samples

Patient ID	Pathological Diagnosis	Age at CSF collection	Gene / HGVSp	Brain VAF (%)	Mean cfDNA VAF (%)	Mean cfDNA VAF from negative controls (%)	p-value
FR-4¶	HME	12.4y	*PIK3CA* / p.Glu545Lys	23	1.358	0.066	< 0.0001ǂ
KR-7	GG	17.3y	*BRAF* / p.Val600Glu	4	0.214	0.073	0.0015ǂ
KR-4	MOGHE	4.2y	*SLC35A2* / p.Gln168*	18	0.145	0.053	0.0014ǂ
FR-5	MOGHE	7.8y	*SLC35A2* / p.Ser212Leufs*9	23	0.000	0.000	NA
KR-2	HME	0.7y	*AKT3* / p.Glu17Lys	4	0.019	0.018	0.9205
KR-5	GG	7.1y	*BRAF* / p.Val600Glu	24	0.064	0.073	0.7443
FR-1	FCD2	11.3y	*MTOR* / p.Ser2215Phe	1	0.031	0.039	0.4398
KR-3	MOGHE	5.2y	*SLC35A2* / p.Glu254*	16	0.000	0.003	0.3388
KR-1	HME	0.1y	*MTOR* / p.Ser2215Phe	23	0.059	0.039	0.3312
FR-3	HME	3.6y	*AKT3* / p.Glu17Lys	12	0.033	0.018	0.1398
FR-2	HME	1.4y	*MTOR* / p.Ala1459Asp	9	0.019	0.008	0.0560
KR-6	GG	7.1y	*BRAF* / p.Val600Glu	13	0.021	0.073	0.0014$

FCD2: Focal cortical dysplasia type 2, HME: Hemimegalencephaly, MOGHE: Malformation of cortical development with oligodendroglial hyperplasia in epilepsy, GG: Ganglioglioma, VAF: variant allele frequency, ǂ: p-values referring to significant positive result, NA: Not applicable, ¶: FR-4 CSF sample was not centrifuged prior freezing, therefore a cellular genomic DNA contamination cannot be excluded, $: the significant p-value obtained in KR-6 highlights a significant lower VAF in the patient compared to the controls, thus confirming the absence of mutation detection. None of the variants was detected in the matched blood samples. Patients (except FR-4) were previously reported: KR-3 and KR-4 [8,11]; FR-1, FR-2 and FR-3 [9]; FR-5 [9,11]; KR-1, KR-2, KR-5 and KR-7 [10]; KR-6 [7,10].



266

267 **Figure 1. Representative ddPCR 2D scatter plot for the targeted detection of mutant alleles.**
268 2D fluorescence amplitude plot shows wild-type-only droplets (HEX+ green circles), mutant-only droplets
269 (FAM+ blue circles), double-negative droplets containing no targeted DNA templates (gray circles) and
270 double-positive droplets containing both WT and mutant DNA templates (orange circles) from bulk brain
271 DNA, and cfDNA for the three positive cases and mutation-negative controls. Each plot is a representation
272 of the mean VAF. VAF: Variant Allele Frequency. Plots were generated in R using the ggplot2 package.

273